Medicare drug plans shift costs to patients under IRA

Written By Tim Coughlin

Important Information regarding Medicare drug plans!

The Inflation Reduction Act (IRA) introduced a $2,000 annual out‑of‑pocket cap starting in 2025 for Medicare Part D prescription drug spending, designed to protect high‑spending beneficiaries. However, a recent white paper from the USC Schaeffer Center reveals that, because most beneficiaries do not reach this cap, many are seeing cost increases as plans respond by increasing deductibles and shifting from flat copayments to coinsurance tied to list prices, thereby moving more costs onto patients even before the cap is met.

Read Medical Ecnomics' full article!

Or read the white paper published by USC Schaeffer Center!

Tim Coughlin

Tim Coughlin has been a licensed insurance agent since 1984. He and his team have helped over 10,000 small businesses, self-employed individuals, families, and Medicare-eligible individuals compare and enroll in quality health, Medicare, and dental plans in the last 30 years. Mr. Coughlin is a recipient of the prestigious “Soaring Eagle”, leading producer award from the National Association of Benefits and Insurance Professionals as well as the National Quality Award and the National Sales Achievement Award. He has consistently earned recognition as a top-producing broker for Blue Shield of CA, United Healthcare, and Western Health Advantage, and other leading carriers.

https://summitoptimalhealthpartners.com/tim-coughlin-author
Previous

Covered California Rates & Plans for 2026
Next

Losing Employer Coverage? Here’s What You Can Do for Health Insurance in Sacramento